Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (AB133319)

Immunohistochemical analysis of Paraffin Embedded Human stomach tissue labelling COX1/Cyclooxygenase 1 with ab133319 at 1/50 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• WB

Lab

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (AB133319)

False colour image of Western blot : Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab133319 was shown to bind specifically to COX1 / Cyclooxygenase 1. A band was observed at 70 kDa in wild-type A431 cell lysates with no signal observed at this size in PTGS1 knockout cell line ab270477 (knockout cell lysate ab270500). To generate this image, wild-type and PTGS1 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

Lanes 1 - 4:

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (ab133319) at 1/1000 dilution

Lanes 1 - 4:

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] - BSA and Azide free (<a href='/ko/products/primary-antibodies/cox1-cyclooxygenase-1-antibody-epr5867-bsa-and-azide-free-ab248471'>ab248471</a>) at 1/1000 dilution

Lane 1:

Wild-type A431 cell lysate at 20 µg

Lane 2:

PTGS1 knockout A431 cell lysate at 20 µg

Lane 3:

C2C12 cell lysate at 20 µg

Lane 4:

MOLT-4 cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Observed band size: 70 kDa

false

• WB

Unknown

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (AB133319)

All lanes:

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (ab133319) at 1/1000 dilution

Lane 1:

C2C12 cell lysate at 10 µg

Lane 2:

A431 cell lysate at 10 µg

Lane 3:

NIH/3T3 cell lysate at 10 µg

Lane 4:

Neuro 2a cell lysate at 10 µg

Lane 5:

L6 cell lysate at 10 µg

Secondary

All lanes:

Goat anti-Rabbit HRP at 1/2000 dilution

Predicted band size: 68 kDa

false

• OI-RD Scanning

Unknown

OI-RD Scanning - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (AB133319)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

• WB

CiteAb

Western blot - Anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] (AB133319)

COX1 / Cyclooxygenase 1 western blot using anti-COX1 / Cyclooxygenase 1 antibody [EPR5867] ab133319. Publication image and figure legend from Hayashi, G., Shen, Y., et al., 2014, Hum Mol Genet, PubMed 25104852.

ab133319 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab133319 please see the product overview.

Frataxin-deficient models have increased expression of COX2 and no alterations in COX1 or cPLA2 expression. (A and D) Cerebellum of KIKO has 4.40-fold increased expression of Cox2 while no changes in Cox1 and cPla2 or the active phosphorylated cPLA2 were observed compared with C57Bl/6 WT. (B) Cerebellum of YG8 hemizygote showed 1.35-fold increased Cox2 expression and no change in Cox1 expression was observed compared with YG8 homozygote. (C) Patient B-lymphocytes had 1.71-fold increased expression of COX2 expression with no changes in COX1 expression compared with healthy B-lymphocytes. The KIKO and YG8 samples were normalized to β-tubulin and B-lymphocyte samples were normalized to β-actin. Bars represent averages ± standard deviations (n = 4, p < 0.05*, p < 0.005**).

false